NCT07578454Active, not recruiting
VRehab-SMA Phase 1.2
Virtual Targeted Rehabilitation for Patients With Spinal Muscular Atrophy: Phase 1.2: Proof-of-concept
Source: ClinicalTrials.gov · Last updated 15 Sept 2026
Brief summary (registry, in English)
Spinal muscular atrophy is a genetic disorder characterized by progressive muscle weakness, severely impacting patients' motor abilities. Several disease modifying therapies have been developed to treat Spinal muscular atrophy which have led to new disease trajectories . According to standard of care guidelines, exercise programs should be designed and monitored by a physical therapist and should include exercises to improve daily life activities. Exercises should be adapted to each patient and can be prescribed with an optimal frequency in various ways. However, of patients with Spinal muscular atrophy, only 20% reported access to endurance exercises and only 6% to mixed exercises. This incompliance to standard of care guidelines is due to manpower limitation and difficulties in engaging with young and sometimes highly disabled children. Our group has been pioneering in developing the UK at-home individualised rehabilitation program. To address this challenge, the Investigators propose the development of an innovative, virtual targeted rehabilitation platform specifically designed for young patients with Spinal muscular atrophy. This technology aims to provide a patient-centric, at-home rehabilitation solution, enabling parents/caregivers to facilitate daily exercises in a more accessible and enjoyable manner. This technology would constitute the first of its kind in Spinal muscular atrophy field, involving the integration of augmented electromyography signals and soft robotic haptic devices into a gamified virtual reality environment. By increasing the frequency and quality of exercise interventions at home, this technology has the potential to significantly address the critical unmet need for consistent rehabilitation. This technology will also serve as a clinical outcome measure for continuous home-based assessments of weaker and less functional population in place of hospital-based assessments.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 15 Apr 2026
- Start date
- 27 May 2026
- Primary completion date
- Apr 2027
- Lead sponsor
- University of Oxford
- Diseases
- Spinal muscular atrophy
- NCT number
- NCT07578454
What you commit to
- Study type: Interventional
- Planned participants: 12
- From 27 May 2026 to the primary completion date, Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treated with any disease-modifying therapy post-symptomatically
- Parent(s)/legal guardian(s)/caregiver(s) able to provide written informed consent and child able to provide assent prior to participation in the study
- Participant with SMA aged 11-15 years
- Treated with any disease-modifying therapy post-symptomatically
- Parent(s)/legal guardian(s)/caregiver(s) able to provide written informed consent and child able to provide assent prior to participation in the study
- Participant with SMA aged 16-18 years
- Treated with any disease-modifying therapy post-symptomatically
Other illness
- Any acute or chronic condition which, according to the investigator, significantly interferes with the use of the device (example: Upper limbs injuries interfering with technology, skin conditions preventing the use of electrodes, etc)
Age
- Participant with SMA aged 6-10 years
- Age: Participants between 6-10 years at Visit 1 (inclusion)
- Age: Participants between 11-15 years at Visit 1 (inclusion)
- Age: Participants between 16-18 years at Visit 1 (inclusion)
Other
- Cohort 2 Inclusion Criteria:
- Genetically confirmed SMA
- A comprehensive understanding of English
- Number of SMN2 copies available
- Functional status available
- Genetically confirmed SMA
- A comprehensive understanding of English
- Number of SMN2 copies available
- Functional status available
- Genetically confirmed SMA
- A comprehensive understanding of English
- Number of SMN2 copies available
- Functional status available
- Able to provide written informed consent
Criteria the registry did not label
- Cohort 1 Inclusion Criteria:
- Person with SMA
- A person living with genetically confirmed SMA aged from 12-18 years
- A good understanding of English or someone who can provide a good understanding of English for me to complete the survey
- A young person living with SMA from 12-15 years of age and who's caregiver/legal guardian gives consent
- A young person living with SMA from 16-18 years of age who provide their own consent
- Caregiver/ Legal Guardian
- A caregiver (legal guardian) of child/young person living with SMA aged from 6-18 years old
- A good understanding of English or someone who can provide a good understanding of English for me to complete the survey
Age in the registry: 6 years to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oxford University Coordinator of this site? Confirm its status | Oxford | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.